
zzso zzso is an inhibitor of human zzso virus type 1 zzso zzso active against zzso susceptible or resistant to older zzso zzso 

We conducted two identical trials in different geographic regions to evaluate the safety and efficacy of zzso as compared with zzso in combination with zzso background therapy, in patients infected with zzso that has zzso drug resistance in whom zzso therapy had zzso Patients were randomly assigned to zzso or zzso in a zzso zzso 

In the combined studies, zzso of 703 zzso patients zzso and 237 in the zzso and zzso groups, zzso received the study zzso zzso of the zzso patients zzso discontinued the study before week zzso zzso was related to the study treatment in 13 of these 17 zzso 7 of the zzso zzso recipients zzso and 6 of the 237 zzso recipients zzso The results of the two studies were zzso At week 16, counting zzso as treatment failure, zzso of zzso zzso recipients zzso had zzso zzso levels below 400 copies per zzso as compared with 99 of 236 zzso recipients zzso zzso zzso of zzso zzso to a level below 50 copies per zzso was achieved at week 16 in zzso of the zzso recipients, as compared with zzso of zzso recipients, and at week 48 in zzso as compared with zzso zzso for both zzso Without adjustment for the length of zzso zzso were detected in zzso of zzso recipients and in zzso of zzso zzso The overall zzso of drug-related adverse events were similar in the zzso and zzso zzso 

In zzso patients with limited treatment options, zzso plus zzso background therapy provided better viral suppression than zzso background therapy alone for at least 48 zzso zzso numbers, zzso and zzso 

